“`html
Allurion Technologies, Inc. (ALUR) reported a quarterly loss of $0.57 per share for the period ending June 2025, better than the Zacks Consensus Estimate of a loss of $0.65. This reflects a significant decline from earnings of $0.25 per share the previous year. The company generated revenues of $3.38 million, which fell short of estimates by 43.21% and was down from $11.77 million year-over-year.
Over the last four quarters, Allurion has exceeded consensus EPS estimates three times, but it has not beaten revenue estimates in the same timeframe. The company’s stock has declined approximately 78% year-to-date, contrasting with a 9.7% gain in the S&P 500. The current consensus for the next quarter projects a loss of $0.54 on revenues of $7.15 million, with a fiscal year estimate of -$3.14 on revenues of $24.53 million.
Allurion holds a Zacks Rank of #4 (Sell), indicating expectations for underperformance in the near future. In the broader context, the Medical – Products industry is ranked in the top 39% of Zacks industries, suggesting some potential upside for well-performing stocks in that sector.
“`
